Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ARGENTINA MENOPAUSE DRUGSMARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 ARGENTINA MENOPAUSE DRUGSMARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 COUNTRY SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 CAUSE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
6 ARGENTINA MENOPAUSE DRUGS MARKET: REGULATIONS
6.1 ARGENTINA
6.2 COUNTRY SPECIFIC REQUIREMENTS
7 PIPELINE ANALYSIS, ARGENTINA MENOPAUSE DRUGS MARKET
8 SUMMARY WRITE UP (ARGENTINA)
8.1 OVERVIEW
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISE IN RESEARCH AND DEVELOPMENT
9.1.2 RISE IN AGEING POPULATION AMONG WOMEN IN ARGENTINA
9.1.3 RISE IN PRODUCT APPROVAL
9.1.4 RISE IN GOVERNMENT INITIATIVES AND ORGANIZATIONS
9.1.5 REIMBURSEMENT FOR MENOPAUSE TREATMENT
9.2 RESTRAINTS
9.2.1 RISE IN COST OF MENOPAUSE DRUGS AND HORMONAL THERAPY
9.2.2 COMPLEXITY IN MENOPAUSE
9.2.3 RISE IN PRODUCT RECALL
9.2.4 LACK OF AWARENESS ABOUT MENOPAUSE
9.3 OPPORTUNITIES
9.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
9.3.2 RISE IN HEALTHCARE EXPENDITURE
9.3.3 USE OF DIETARY SUPPLEMENTS
9.4 CHALLENGES
9.4.1 SIDE EFFECTS CAUSED DUE TO DRUGS TAKEN FOR MENOPAUSE TREATMENT
9.4.2 STRINGENT REGULATIONS
10 IMPACT OF COVID-19 ON ARGENTINA MENOPAUSE DRUGS MARKET
10.1 IMPACT ON PRICE
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISIONS BY MANUFACTURERS
10.5 CONCLUSION
11 ARGENTINA MENOPAUSE DRUGS MARKET, BY STAGES
11.1 OVERVIEW
11.2 POSTMENOPAUSE
11.3 PERIMENOPAUSE
11.4 MENOPAUSE
12 ARGENTINA MENOPAUSE DRUGS MARKET, BY TYPE
12.1 OVERVIEW
12.2 NON-HORMONAL THERAPY
12.2.1 MEDICATION
12.2.1.1 PAROXETINE
12.2.1.2 ANTI-DEPRESSANTS
12.2.1.3 GABAPENTIN
12.2.1.4 CLONIDINE
12.2.1.5 OSPEMIFENE
12.2.1.6 OTHERS
12.2.2 SUPPLEMENTS
12.2.2.1 HERBAL SUPPLEMENTS
12.2.2.1.1 GINSENG
12.2.2.1.2 ASHWAGANDHA
12.2.2.1.3 OTHERS
12.2.2.2 VITAMIN D
12.2.2.3 OTHERS
12.3 HORMONAL THERAPY
12.3.1 ESTROGEN
12.3.1.1 17 B- ESTRADIOL
12.3.1.2 CONJUGATED ESTROGEN
12.3.1.3 ESTRADIOL HEMIHYDRATE
12.3.1.4 ESTERIFIED ESTROGEN
12.3.1.5 ESTERIFIED ACETATE
12.3.1.6 ESTROPIPATE
12.3.1.7 OTHERS
12.3.2 COMBINED ESTROGEN & PROGESTOGEN DRUGS
12.3.2.1 17 B- ESTRADIOL (E) + NORETHINODRONE ACETATE (P)
12.3.2.2 CONJUGATED ESTROGENS (E) + MEDROXYPROGESTERONE ACETATE (P)
12.3.2.3 ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P)
12.3.2.4 OTHERS
12.3.3 MEDROXYPROGESTERONE ACETATE
13 ARGENTINA MENOPAUSE DRUGS MARKET, BY MENOPAUSE SYMPTOMS
13.1 OVERVIEW
13.2 VASOMOTOR SYMPTOMS
13.2.1 HORMONAL THERAPY
13.2.2 NON- HORMONAL THERAPY
13.3 ATROPHIC VAGINITIS
13.3.1 HORMONAL THERAPY
13.3.2 NON- HORMONAL THERAPY
13.4 DYSPAREUNIA
13.4.1 NON- HORMONAL THERAPY
13.4.2 HORMONAL THERAPY
13.5 OSTEOPOROSIS
13.5.1 NON- HORMONAL THERAPY
13.5.2 HORMONAL THERAPY
13.6 JOINT PAIN
13.6.1 NON- HORMONAL THERAPY
13.6.2 HORMONAL THERAPY
13.7 DEPRESSION
13.7.1 NON- HORMONAL THERAPY
13.7.2 HORMONAL THERAPY
13.8 WEIGHT GAIN
13.8.1 HORMONAL THERAPY
13.8.2 NON- HORMONAL THERAPY
13.9 OTHERS
14 ARGENTINA MENOPAUSE DRUGS MARKET, BY DOSAGE FORM
14.1 OVERVIEW
14.2 TABLET
14.3 CREAM
14.4 PATCH/FILM
14.5 RINGS
14.6 GEL
14.7 INJECTION SHOT
14.8 SPRAY
14.9 OTHERS
15 ARGENTINA MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.3 PARENTERAL
15.3.1 INTRAVENOUS
15.3.2 SUBCUTANEOUS
15.3.3 OTHERS
15.4 TRANSDERMAL
15.5 VAGINAL
15.6 OTHERS
16 ARGENTINA MENOPAUSE DRUGS MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITAL
16.3 CLINICS
16.4 HOME HEALTHCARE
16.5 OTHERS
17 ARGENTINA MENOPAUSE DRUGS MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 RETAIL PHARMACY
17.3 HOSPITAL PHARMACY
17.4 ONLINE PHARMACY
18 ARGENTINA MENOPAUSE DRUGS MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: ARGENTINA
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 PFIZER INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENTS
20.2 BAYER AG
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENTS
20.3 NOVARTIS AG
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.4 LABORATORIOS BAGO S.A.
20.4.1 COMPANY SNAPSHOT
20.4.2 PRODUCT PORTFOLIO
20.4.3 RECENT DEVELOPMENTS
20.5 GLAXOSMITHKLINE PLC(2021)
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENTS
20.6.4.1 PARTNERSHIP
20.6.4.2 PRODUCT LAUNCH
20.7 NOVO NORDISK A/S
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.8 ABBVIE INC.
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENTS
20.9 ABBOTT
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENT
20.1 ACHE LABORATÓRIOS FARMACÊUTICOS S/A
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENTS
20.11 GADOR S.A.
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENTS
20.12 LABORATORIOS BERNABO S.A.
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENTS
20.13 LABORATORIO ELEA PHOENIX S.A.
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.13.3.1 PRODUCT LAUNCH
20.14 QUIMICA MONTPELLIER S.A.
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENTS
20.15 ROEMMERS SAICF
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENTS
20.16 TEMIS LOSLATO
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
List of Table
TABLE 1 ARGENTINA MENOPAUSE DRUGS MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 2 ARGENTINA MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 3 ARGENTINA NON –HORMONAL THERAPY IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 ARGENTINA MEDICATION IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 5 ARGENTINA SUPPLEMENTS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 ARGENTINA HERBAL SUPPLEMENTS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 ARGENTINA HORMONAL THERAPY IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 ARGENTINA ESTROGEN IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 ARGENTINA COMBINED ESTROGEN & PROGESTOGEN DRUGS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 ARGENTINA MENOPAUSE DRUGS MARKET, BY MENOPAUSE SYMPTOMS, 2020-2029 (USD MILLION)
TABLE 11 ARGENTINA VASOMOTOR SYMPTOMS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 ARGENTINA ATROPHIC VAGINITIS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 ARGENTINA DYSPAREUNIA IN MENOPAUSE DRUGS MARKET, BY TYPE2020-2029 (USD MILLION)
TABLE 14 ARGENTINA OSTEOPOROSIS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 ARGENTINA JOINT PAIN IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 ARGENTINA DEPRESSION IN MENOPAUSE DRUGS MARKET, BY TYPE , 2020-2029 (USD MILLION)
TABLE 17 ARGENTINA WEIGHT GAIN IN MENOPAUSE DRUGS MARKET, BY TYPE , 2020-2029 (USD MILLION)
TABLE 18 ARGENTINA MENOPAUSE DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 19 ARGENTINA MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 20 ARGENTINA PARENTERAL IN MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 21 ARGENTINA MENOPAUSE DRUGSMARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 22 ARGENTINA MENOPAUSE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 ARGENTINA MENOPAUSE DRUGSMARKET: SEGMENTATION
FIGURE 2 ARGENTINA MENOPAUSE DRUGSMARKET: DATA TRIANGULATION
FIGURE 3 ARGENTINA MENOPAUSE DRUGSMARKET: DROC ANALYSIS
FIGURE 4 ARGENTINA MENOPAUSE DRUGSMARKET: REGIONAL VS COUNTRY ANALYSIS
FIGURE 5 ARGENTINA MENOPAUSE DRUGSMARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ARGENTINA MENOPAUSE DRUGSMARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ARGENTINA MENOPAUSE DRUGS MARKET: DBMR POSITION GRID
FIGURE 8 ARGENTINA MENOPAUSE DRUGSMARKET: VENDOR SHARE ANALYSIS
FIGURE 9 ARGENTINA MENOPAUSE DRUGS MARKET: END USER COVERAGE GRID
FIGURE 10 ARGENTINA MENOPAUSE DRUGS MARKET: SEGMENTATION
FIGURE 11 RISE IN PRODUCT APPPROVALS IS EXPECTED TO DRIVE THE ARGENTINA MENOPAUSE DRUGS MARKET FROM 2022 TO 2029
FIGURE 12 POSTMENOPAUSE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE ARGENTINA MENOPAUSE DRUGS MARKET FROM 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ARGENTINA MENOPAUSE DRUGS MARKET
FIGURE 14 ESTIMATED AGE OF WOMEN, AGED ABOVE 45 YEARS, UNDERGOING MENOPAUSE IN 2020
FIGURE 15 ARGENTINA MENOPAUSE DRUGS MARKET, BY STAGES, 2021
FIGURE 16 ARGENTINA MENOPAUSE DRUGS MARKET, BY STAGES, 2020-2029 (USD MILLION)
FIGURE 17 ARGENTINA MENOPAUSE DRUGS MARKET, BY STAGES, CAGR (2022-2029)
FIGURE 18 ARGENTINA MENOPAUSE DRUGS MARKET, BY STAGES, LIFELINE CURVE
FIGURE 19 ARGENTINA MENOPAUSE DRUGS MARKET, BY TYPE, 2021
FIGURE 20 ARGENTINA MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
FIGURE 21 ARGENTINA MENOPAUSE DRUGS MARKET, BY TYPE, CAGR (2022-2029)
FIGURE 22 ARGENTINA MENOPAUSE DRUGS MARKET, BY TYPE, LIFELINE CURVE
FIGURE 23 ARGENTINA MENOPAUSE DRUGS MARKET, BY MENOPAUSE SYMPTOMS, 2021
FIGURE 24 ARGENTINA MENOPAUSE DRUGS MARKET, BY MENOPAUSE SYMPTOMS, 2020-2029 (USD MILLION)
FIGURE 25 ARGENTINA MENOPAUSE DRUGS MARKET, BY MENOPAUSE SYMPTOMS, CAGR (2022-2029)
FIGURE 26 ARGENTINA MENOPAUSE DRUGS MARKET, BY MENOPAUSE SYMPTOMS, LIFELINE CURVE
FIGURE 27 ARGENTINA MENOPAUSE DRUGS MARKET, BY DOSAGE FORM, 2021
FIGURE 28 ARGENTINA MENOPAUSE DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
FIGURE 29 ARGENTINA MENOPAUSE DRUGS MARKET, BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 30 ARGENTINA MENOPAUSE DRUGS MARKET, BY DOSAGE FORM, LIFELINE CURVE
FIGURE 31 ARGENTINA MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021
FIGURE 32 ARGENTINA MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 33 ARGENTINA MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 34 ARGENTINA MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 ARGENTINA MENOPAUSE DRUGS MARKET, BY END USER, 2021
FIGURE 36 ARGENTINA MENOPAUSE DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
FIGURE 37 ARGENTINA MENOPAUSE DRUGS MARKET, BY END USER, CAGR (2022-2029)
FIGURE 38 ARGENTINA MENOPAUSE DRUGS MARKET, BY END USER, LIFELINE CURVE
FIGURE 39 ARGENTINA MENOPAUSE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021
FIGURE 40 ARGENTINA MENOPAUSE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 41 ARGENTINA MENOPAUSE DRUGS MARKET, BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 42 ARGENTINA MENOPAUSE DRUGS MARKET, BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 ARGENTINA MENOPAUSE DRUGS MARKET: COMPANY SHARE 2021 (%)
